{"id":29334,"date":"2025-10-06T12:22:59","date_gmt":"2025-10-06T16:22:59","guid":{"rendered":"https:\/\/www.mesotheliomahope.com\/?page_id=29334"},"modified":"2025-12-23T17:45:31","modified_gmt":"2025-12-23T22:45:31","slug":"avelumab","status":"publish","type":"page","link":"https:\/\/www.mesotheliomahope.com\/treatment\/immunotherapy\/avelumab\/","title":{"rendered":"Bavencio\u00ae (Avelumab) for Mesothelioma Immunotherapy"},"content":{"rendered":"

What Is Bavencio (Avelumab) for Mesothelioma?<\/h2>\n

Avelumab, also known by its brand name Bavencio, is a type of immunotherapy for mesothelioma<\/a>. It’s co-developed by Merck KGaA (Germany) and Pfizer.<\/p>\n

Immunotherapy helps the immune system more easily detect mesothelioma cells. Avelumab is part of a group of immunotherapy medications called immune checkpoint inhibitors<\/a>. It targets a specific protein made by mesothelioma cells called PD-L1, which serves as a \u201ccheckpoint\u201d for the immune system.<\/p>\n

Mesothelioma cells use PD-L1 to hide from T-cells made by the immune system to fight threats like cancer. Avelumab stops this from happening so that malignant mesothelioma cells can be killed. Avelumab has not been approved by the U.S. Food and Drug Administration (FDA) to treat mesothelioma<\/a>. It is currently being studied in clinical trials to evaluate its safety and effectiveness.<\/p>\n

Key Facts on Avelumab Immunotherapy for Mesothelioma<\/h3>\n